Treatment Resistant Major Depressive Disorder Clinical Trial
Official title:
Augmentation Versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With Treatment Resistant Depression (ASCERTAIN-TRD)
This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing, stable and adequate antidepressant therapy (ADT). Adequate ADT is defined as a therapeutically sufficient dose for a sufficient treatment period, which would be expected to be effective as listed in the MGH Antidepressant Treatment Response Questionnaire (ATRQ). Patients will be randomized in a 1:1:1 fashion to one of three open-label treatment arms: a) aripiprazole augmentation, b) rTMS augmentation, and c) switching to venlafaxine XR or Duloxetine.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT05323019 -
Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression
|
Phase 2 | |
| Completed |
NCT02741791 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
|
Phase 3 | |
| Terminated |
NCT03254017 -
Remotely Programmed Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression: An Open Label Pilot Trial
|
N/A | |
| Withdrawn |
NCT05438758 -
Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study
|
Phase 2 | |
| Active, not recruiting |
NCT01798407 -
DBS of the Lateral Habenula in Treatment-Resistant Depression
|
N/A | |
| Completed |
NCT00986479 -
This is a Study to Determine the Antidepressant Effects of AZD6765
|
Phase 2 |